XLO — Xilio Therapeutics Share News
0.000.00%
Last trade - 00:00- $49.81m
- -$86.23m
- $43.77m
Brief: Xilio Starts Phase 2 Trial for XTX301, Hits $17.5M Milestone in Gilead License Deal
Xilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Catalyst Pharmaceuticals Appoints Daniel Curran, MD, To Its Board Of Directors
Xilio Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Xilio Therapeutics Appoints Akintunde Bello, Ph.D., To Its Board Of Directors
Brief: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus
U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital
Xilio Therapeutics tumbles after $50 mln equity offering
U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera
Brief: Xilio Therapeutics Announces Proposed Public Offering
U.S. STOCKS ON THE MOVE-Moderna, Blueprint Medicines, Boeing
Xilio Therapeutics drops on equity raise plans
Brief: Xilio Therapeutics Announces Updated Phase 2 Data For Vilastobart, A Tumor-Activated Anti-Ctla-4, In Combination With Atezolizumab In Patients With Metastatic Microsatellite Stable Colorectal Cancer
Xilio Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Xilio Therapeutics Q1 Net Income USD -13.265 Million
Brief: Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time
Brief: Xilio Therapeutics Q4 Net Income USD -13.093 Million